Financial Performance - Q3 2025 net product revenues reached $99.2 million, a 122% increase compared to Q3 2024[28,33] - Net product revenues increased by 22% quarter over quarter[28,33] - The company reported a net profit of $7.4 million in Q3 2025, a significant improvement from a net loss of $41.5 million in Q3 2024[33] - Cash, cash equivalents, and marketable securities totaled $191.4 million as of September 30, 2025[35] - The company projects product sales of $455-$470 million in 2026[138] ZORYVE Product and Market - Weekly TRx (Total Prescriptions) for the ZORYVE portfolio reached approximately 17,500 on a rolling 4-week basis[29] - TRx growth for ZORYVE showed a 13% increase compared to Q2 2025 and a 92% increase compared to Q3 2024[30] - The company estimates a total addressable market of 30 million patients across Psoriasis (PsO), Atopic Dermatitis (AD), and Seborrheic Dermatitis (SD)[50,84] - The serviceable obtainable market (SOM) is estimated at 8 million patients receiving topical prescriptions in dermatology[50] Growth Strategy - The company aims to expand ZORYVE into new markets and indications, including vitiligo and hidradenitis suppurativa (HS)[39,119] - Peak sales potential for current indications is estimated at $2.3 - $3.0 billion, with an additional $0.3 - $0.5 billion from label expansion and data generation[122]

Financial Performance - Q2 2025 net product revenue reached $81.5 million, a 164% increase compared to Q2 2024[28,39] - Net product revenues increased by 28% quarter-over-quarter from Q1 2025 to Q2 2025[39,73] - Net loss decreased by 70% from $(52.3) million in Q2 2024 to $(15.9) million in Q2 2025[73] - Cash, cash equivalents, and marketable securities totaled $191.1 million as of June 30, 2025[75] Product & Commercial Updates - ZORYVE portfolio achieved approximately 16,500 weekly total prescriptions on a rolling 4-week basis[40] - Total prescriptions growth was +13% from Q1 2025 to Q2 2025 and +117% compared to Q2 2024[41] - Over 80% of ZORYVE prescriptions are covered by insurance[49] - Launched ZORYVE foam 0.3% for plaque psoriasis of the scalp and body[28] Research & Development - Anticipated approval of ZORYVE cream 0.05% for atopic dermatitis ages 2-5 with target PDUFA October 2025[28,58] - Phase 2 trial initiated for ZORYVE cream 0.05% in ages 3-24 months for atopic dermatitis[58,62]

Financial Performance - Q1 2025 net product revenue reached $63.8 million for ZORYVE®[28], a 196% increase compared to the prior year[37] - Total revenues for Q1 2025 were $65.8 million, a $16.3 million increase year-over-year[73] - Net loss for Q1 2025 was $(25.1) million, an improvement of $10.3 million compared to Q1 2024[73] - Cash, cash equivalents, and marketable securities totaled $198.7 million as of March 31, 2025[77] Commercial Progress - Prescription demand for ZORYVE grew by 10%[28] from Q4 2024 to Q1 2025[39] - Over 80% of ZORYVE prescriptions are covered by insurance[43] - ZORYVE's TRx share in the branded topical segment has grown from 11% to 41%[50] - The branded topical segment grew by 50%[47] Pipeline and Regulatory Milestones - Anticipated FDA approval of ZORYVE foam 0.3% for scalp & body psoriasis with a target PDUFA date in May 2025[28, 59] - The company submitted a supplemental New Drug Application (sNDA) for ZORYVE Cream 0.05% in ages 2-5 for Atopic Dermatitis with an anticipated target action date of October 13, 2025[59]